Case studyBone morphogenetic protein (BMP-2) usage and cancer correlation: An analysis of 10,416 spine fusion patients from a multi-center spine registry

•This is an independent, non-industry supported study-one of the few that exists in the literature.•Multi-center spine implant registry data used.•No significant increase in cancer risk associated with use of BMP for spinal fusion in doses between 1.05 and 12 mg.